



Boca Raton, FL – December 21, 2010

Amzak announces investment in IGI Laboratories

Amzak Capital Management is pleased to announce that it has agreed to extend a \$3,000,000 credit facility to IGI Laboratories, Inc. More information on the transaction can be found by visiting IGI laboratories (AMEX: IG) SEC filings.

IGI develops, manufactures, fills and packages topical semi-solid and liquid products for cosmetic, cosmeceutical and pharmaceutical customers. The Company's products are used for cosmetic, cosmeceutical and prescription applications for the treatment of symptoms of dermatitis, acne, psoriasis and eczema. The Company is building upon this foundation by filing its own ANDAs and continuing to expand into the prescription pharmaceutical arena. The Company's strategy is based upon three initiatives: increasing the current contract services business, developing a portfolio of generic formulations in topical dosage forms and creating unique opportunities around its licensed Novasome® technology. All of its product development and manufacturing is performed at its 25,000 sq.ft. facility in Buena, NJ.

Amzak Capital Management is the investment vehicle for the Kazma family. Amzak makes business development, debt and equity investments in a range of industries domestically and internationally. The group considers investments from a control perspective as well as minority investments across the capital structure, and has a particularly strong track record in the media and telecommunications sectors. Amzak is headquartered in Boca Raton, FL.

For more information about IGI Laboratories visit www.igilabs.com.

For more information about Amzak Capital Management visit www.amzak.com.

CONTACT

Scot Fischer

Amzak Capital Management, Managing Partner

Telephone: 561-953-4164

Email: sfischer@amzak.com